CONNEQT Health

CONNEQT Health ROE

The Return on Equity (ROE) of CONNEQT Health (CQT.AX) as of Nov 14, 2026 is -2,871.93 %. In the previous year, Return on Equity (ROE) was -165.51 % — a change of 1,635.16% (lower).

ROE

-2,871.93 %

YoY

1,635.16%

Last updated:

In 2025, CONNEQT Health's return on equity (ROE) was -2,871.93 %, a 1,635.16% increase from the -165.51 % ROE in the previous year.

The CONNEQT Health ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-64.43 AUD
Jan 1, 2019
-42.86 AUD
Jan 1, 2020
-56.47 AUD
Jan 1, 2021
-70.11 AUD
Jan 1, 2022
-178.63 AUD
Jan 1, 2023
2,523.61 AUD
Jan 1, 2024
-165.51 AUD
Jan 1, 2025
-2,871.93 AUD
The CONNEQT Health ROE history
YEARROEYoY
-2,871.93 %+1,635.16%
-165.51 %-106.56%
2,523.61 %-1,512.78%
-178.63 %+154.80%
-70.11 %+24.15%
-56.47 %+31.75%
-42.86 %-33.47%
-64.43 %-80.39%
-328.46 %+114.66%
-153.02 %+360.47%
-33.23 %-59.02%
-81.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CONNEQT Health Stock analysis

What does CONNEQT Health do? CardieX Ltd. generates revenue through its medical device business focused on cardiovascular management, targeting healthcare providers and pharmaceutical companies. The company offers clinical trial services across three geographic segments: Americas, Europe (including Middle East and Africa), and Asia Pacific (covering Asia and Australia/New Zealand). These services include study protocol assistance, operator training, data management, and technical support for global pharmaceutical trials. SphygmoCor technology is a key product used in clinical trials for therapeutic areas such as hypertension, renal disease, and heart failure. The firm's revenue streams are derived from its clinical trial services and SphygmoCor technology, which are sold to pharmaceutical companies conducting global trials. The Americas segment handles the global pharmaceutical trials business, while Europe and Asia Pacific segments support regional trial operations. SphygmoCor technology is specifically utilized in trials for cardiovascular and metabolic conditions, including COPD and diabetes. CardieX Ltd. serves pharmaceutical companies and healthcare institutions requiring cardiovascular management solutions and clinical trial support. Its products and services are tailored to therapeutic areas like hypertension, renal disease, heart failure, and inflammatory processes, with a focus on automated data transfer and expert over-read services for trial accuracy. CONNEQT Health is one of the most popular companies on Eulerpool.

ROE Details

Decoding CONNEQT Health's Return on Equity (ROE)

CONNEQT Health's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing CONNEQT Health's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

CONNEQT Health's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in CONNEQT Health’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about CONNEQT Health stock

Return on Equity (ROE) of CONNEQT Health is -2,871.93 % in 2025.

Return on Equity (ROE) of CONNEQT Health changed from -165.51 % to -2,871.93 %, representing a 1,635.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) CONNEQT Health since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s CONNEQT Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CONNEQT Health

All Key Metrics — CONNEQT Health